1. Scrip
  2. >>Business

BioNTech Expands COVID-19 Vaccine Output Again, Forecasts $10bn Revenues

Also Increasing Oncology Trials

 
• By Andrew McConaghie

Success of the vaccine will fuel the company’s push into immunotherapy, as it reported first commercial sales.

Mainz, Rheinland-Pfalz, Germany-9. September 2020 Biontech building in Mainz with the sun shining and waving flags
BioNTech has been transformed into a European biotech powerhouse, with a market cap of $26bn and vaccines revenues to fund its ambitions in immunotherapy.

BioNTech and Pfizer are set to increase production of their COVID-19 vaccine Comirnaty to 2.5 billion doses by the end of 2021, just as they look to expand into new geographies and younger age groups.

This is thanks in part to BioNTech’s new facility in Marburg, Germany, coming on stream, helping to lift the partners’ output above the 2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

More from Scrip

Atara Does An About Face As FDA Lifts Ebvallo Hold

 
• By Alaric DeArment

The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.